These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 22161470)
21. Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity. Kuzdas-Wood D; Fellner L; Premstaller M; Borm C; Bloem B; Kirik D; Wenning GK; Stefanova N BMC Neurosci; 2015 Dec; 16():86. PubMed ID: 26627686 [TBL] [Abstract][Full Text] [Related]
22. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Marmion DJ; Rutkowski AA; Chatterjee D; Hiller BM; Werner MH; Bezard E; Kirik D; McCown T; Gray SJ; Kordower JH Neurobiol Dis; 2021 Jan; 148():105184. PubMed ID: 33221532 [TBL] [Abstract][Full Text] [Related]
23. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Stefanova N; Kaufmann WA; Humpel C; Poewe W; Wenning GK Acta Neuropathol; 2012 Jul; 124(1):51-65. PubMed ID: 22491959 [TBL] [Abstract][Full Text] [Related]
24. Alpha-synuclein transgenic mice: relevance to multiple system atrophy. Fillon G; Kahle PJ Mov Disord; 2005 Aug; 20 Suppl 12():S64-6. PubMed ID: 16092093 [TBL] [Abstract][Full Text] [Related]
25. Expanding the spectrum of neuronal pathology in multiple system atrophy. Cykowski MD; Coon EA; Powell SZ; Jenkins SM; Benarroch EE; Low PA; Schmeichel AM; Parisi JE Brain; 2015 Aug; 138(Pt 8):2293-309. PubMed ID: 25981961 [TBL] [Abstract][Full Text] [Related]
26. Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration: frontotemporal lobar degeneration associated with α-synuclein. Aoki N; Boyer PJ; Lund C; Lin WL; Koga S; Ross OA; Weiner M; Lipton A; Powers JM; White CL; Dickson DW Acta Neuropathol; 2015 Jul; 130(1):93-105. PubMed ID: 25962793 [TBL] [Abstract][Full Text] [Related]
27. FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models. Vidal-Martinez G; Segura-Ulate I; Yang B; Diaz-Pacheco V; Barragan JA; De-Leon Esquivel J; Chaparro SA; Vargas-Medrano J; Perez RG Exp Neurol; 2020 Mar; 325():113120. PubMed ID: 31751571 [TBL] [Abstract][Full Text] [Related]
28. Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Jellinger KA Mov Disord; 2014 Dec; 29(14):1720-41. PubMed ID: 25297524 [TBL] [Abstract][Full Text] [Related]
29. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Bassil F; Fernagut PO; Bezard E; Pruvost A; Leste-Lasserre T; Hoang QQ; Ringe D; Petsko GA; Meissner WG Proc Natl Acad Sci U S A; 2016 Aug; 113(34):9593-8. PubMed ID: 27482103 [TBL] [Abstract][Full Text] [Related]
30. Cellular pathology in multiple system atrophy. Wakabayashi K; Takahashi H Neuropathology; 2006 Aug; 26(4):338-45. PubMed ID: 16961071 [TBL] [Abstract][Full Text] [Related]
31. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy. Herrera-Vaquero M; Bouquio D; Kallab M; Biggs K; Nair G; Ochoa J; Heras-Garvin A; Heid C; Hadrovic I; Poewe W; Wenning GK; Klärner FG; Schrader T; Bitan G; Stefanova N Biochim Biophys Acta Mol Basis Dis; 2019 Nov; 1865(11):165513. PubMed ID: 31319154 [TBL] [Abstract][Full Text] [Related]
32. Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy. Mészáros L; Hoffmann A; Wihan J; Winkler J Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316335 [TBL] [Abstract][Full Text] [Related]
33. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Ubhi K; Rockenstein E; Mante M; Patrick C; Adame A; Thukral M; Shults C; Masliah E Neuroreport; 2008 Aug; 19(13):1271-6. PubMed ID: 18695506 [TBL] [Abstract][Full Text] [Related]
34. High dose levodopa therapy is not toxic in multiple system atrophy: experimental evidence. Stefanova N; Köllensperger M; Hainzer M; Cenci A; Poewe W; Wenning GK Mov Disord; 2007 May; 22(7):969-73. PubMed ID: 17427936 [TBL] [Abstract][Full Text] [Related]
35. Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. Sturm E; Fellner L; Krismer F; Poewe W; Wenning GK; Stefanova N Neurotherapeutics; 2016 Oct; 13(4):871-879. PubMed ID: 27259295 [TBL] [Abstract][Full Text] [Related]
37. Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy. Fernagut PO; Meissner WG; Biran M; Fantin M; Bassil F; Franconi JM; Tison F Synapse; 2014 Mar; 68(3):98-106. PubMed ID: 24243499 [TBL] [Abstract][Full Text] [Related]
38. The neuropathology, pathophysiology and genetics of multiple system atrophy. Ahmed Z; Asi YT; Sailer A; Lees AJ; Houlden H; Revesz T; Holton JL Neuropathol Appl Neurobiol; 2012 Feb; 38(1):4-24. PubMed ID: 22074330 [TBL] [Abstract][Full Text] [Related]
39. Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1. Jellinger KA J Alzheimers Dis; 2018; 62(3):1141-1179. PubMed ID: 28984582 [TBL] [Abstract][Full Text] [Related]
40. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Ozawa T; Paviour D; Quinn NP; Josephs KA; Sangha H; Kilford L; Healy DG; Wood NW; Lees AJ; Holton JL; Revesz T Brain; 2004 Dec; 127(Pt 12):2657-71. PubMed ID: 15509623 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]